Cosentyx Patient Booklet

COSENTYX® is indicated for the treatment of:1

  • Moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy.

  • Active psoriatic arthritis (PsA) in adults with inadequate response to prior disease-modifying anti-rheumatic drug (DMARD) therapy, as monotherapy or in combination with methotrexate.

  • Active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.

  • Active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs).

  • Active enthesitis-related arthritis (ERA) and active juvenile psoriatic arthritis (JPsA) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

  • Moderate to severe hidradenitis suppurativa (HS; acne inversa) in adult patients with an inadequate response to conventional systemic therapy.

COSENTYX® should be initiated and supervised by a physician experienced in the diagnosis and treatment of its approved indications.

SensoReady® 150 mg injection video

This page contains a 6-minute video demonstrating how to prepare and deliver Cosentyx with the SensoReady® 150 mg pen.

Disclaimer: 

This video is intended for patients who have been prescribed Cosentyx® (secukinumab) for self-injection with a pre-filled pen by their healthcare professionals, and who have received the necessary training for proper injection of the product. This video does not replace the training that is necessary to be given by the doctor, nurse, or pharmacist.

Patients should consult their physician if they have any questions.

Cosentyx Sensoready 150mg pen

For full prescribing information on Cosentyx, click here.

Reference:

  1. Cosentyx Prescribing Information, Singapore.